CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity
For lifters running it alongside BPC-157 and TB-500 in an injury block, this angiogenic signal layers cleanly with BPC-157's vascular effects and TB-500's cell-migration mechanics the reason the "healing trio" has stuck around
5-Amino-1MQ is a lab-made compound (not actually a peptide, despite being listed as one) that blocks an enzyme called NNMT, which normally drains a molecule your cells need for energy (NAD+) and slows your metabolism down
Unlicensed med spa owners causing facial paralysis and infections
All this to come together to make glutathione
This multi-axis neuroendocrine regulatory profile positions DSIP as a broad hypothalamic-pituitary axis modulator, not merely a sleep-specific peptide, and makes it a research tool for studying the neuroendocrine consequences of altered sleep homeostasis and circadian rhythm disruption
